Skip to main content
SpringerLink
Log in

Chemotherapy of Pancreatic, Colorectal and Gastric Cancer

  • Chapter
Gastrointestinal Cancer 1

Part of the book series: Cancer Treatment and Research ((CTAR,volume 3))

  • 31 Accesses

Abstract

Pancreatic cancer currently represents the fifth leading cause of cancer death in this country; its toll is surpassed only by lung, colon and rectum, breast, and prostate cancer [1]. The only therapeutic modality with the potential for cure is surgery, and even with surgery the cure rate is exceedingly low. Most patients present with localized or regional disease but an attempt at resection is warranted in only a minor fraction because of involvement of major abdominal structures [2]. Gudjonsson et al. [3] have analyzed 100 patients from their own institution and reviewed a number of series in the literature. They calculate from their own patients a median survival of 5 1/2 months from the time of first symptoms, a median survival of four months from the time of histologically confirmed diagnosis, a one year survival of 10% and a five year survival of 1% (a single patient who survived eight years with a palliative bypass procedure but without resection). They estimate from review of the literature that 80% of patients with carcinoma of the pancreas come to abdominal exploration; however, only 10–15% of these are resected for cure. Fewer than 1% survive five years, and many institutions have failed to record their first five year survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Cancer Society. Cancer facts and figures, 1979. New York.

    Google Scholar 

  2. McDermott MV, Bartlett MK: Pancreaticoduodenal cancer. N Engl J Med 248:927–931, 1953.

    Article  PubMed  Google Scholar 

  3. Gudjonsson B, Livstone EM, Spiro HM: Cancer of the pancreas: diagnostic accuracy and survival statistics. Cancer 42:2494–2506, 1978.

    Article  PubMed  CAS  Google Scholar 

  4. Isaacson R, Weiland LH, Mcllrath DC: Biopsy of the pancreas. Arch Surg 109:227–230, 1974.

    PubMed  CAS  Google Scholar 

  5. Brooks JR: Operative approach to pancreatic carcinoma. Semin Oncol 6:357–367, 1979.

    PubMed  CAS  Google Scholar 

  6. Hancke S, Holms HH, Koch F: Ultrasonically guided percutaneous fine needle biopsy of the pancreas. Surg Gynecol. Obstet 140:361–364, 1975.

    PubMed  CAS  Google Scholar 

  7. Beazley RM: Percutaneous needle biopsy for diagnosis of pancreatic cancer. Semin Oncol 6:344–346, 1979.

    PubMed  CAS  Google Scholar 

  8. Tsuchiya R, Henmi T, Kondo N et al.: Endoscopic aspiration biopsy of the pancreas, gastroenterology 73:1050–1053, 1977.

    PubMed  CAS  Google Scholar 

  9. Kawanishi H, Pollard HM: Endoscopic evaluation of cancer of the pancreas. Semin Oncol 6:309–317, 1979.

    PubMed  CAS  Google Scholar 

  10. Levin B, ReMine WH, Herman RE et al.: Cancer of the pancreas. Am J Surg 135:185–191, 1978.

    Article  PubMed  CAS  Google Scholar 

  11. MacDonald JS, Widerlite L, Schein PS: Biology, diagnosis and chemotherapeutic management of pancreatic malignancy. Adv. Pharmacol. Chemother. 14:107–141, 1977.

    Article  PubMed  CAS  Google Scholar 

  12. Carter SK, Comis RL: Adenocarcinoma of the pancreas, prognostic variables, and criteria of response in cancer therapy. In: Response in cancer therapy: prognostic factors and criteria of response, Staquet MJ (ed). New York: Raven Press, 1975, pp 237–253.

    Google Scholar 

  13. Reitemeier RJ, Moertel CG, Hahn RG: Comparative evaluation of palliation with fiuorom-etholone (NCSA-33001), 5-fiuorouracil (NSC-19893), and combined fluorometholone and 5-fluorouracil in advanced gastrointestinal cancer. Cancer Chemother. Rep 51:77–80, 1967.

    PubMed  CAS  Google Scholar 

  14. Stolinsky DC, Pugh RP, Bateman JR: 5-Fluorouracil (NSC-19893) therapy for pancreatic carcinoma: comparison of oral and intravenous routes. Cancer Chemother Rep 59:1031–1033, 1975.

    PubMed  CAS  Google Scholar 

  15. Moertel CG, Reitemeier RJ, Hahn RG: Therapy with mitomycin-C. In: Advanced gastrointestinal cancer/clinical management and chemotherapy, Moertel CG, Reitemeier RJ (eds). New York: Harper & Row, 1969, pp 168–175.

    Google Scholar 

  16. Moertel CG: Therapy of advanced gastrointestinal cancer with the nitrosoureas. Cancer Chemother. Rep 4:27–34, 1973.

    CAS  Google Scholar 

  17. Douglass HO Jr, Lavin PT, Moertel CG: Nitrosoureas: useful agents for treatment of advanced gastrointestinal cancer. Cancer Treat Rep 60:769–780, 1976.

    PubMed  Google Scholar 

  18. Rakieten N, Rakieten ML, Nadkarni MV: Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 29:91–98, 1963.

    Google Scholar 

  19. Dupriest RW, Hintington M, Massey WH et al.: Streptozotocin therapy in 22 cancer patients. Cancer 35:358–367, 1974.

    Article  Google Scholar 

  20. Stolkinsky DC, Sadoff L, Braunwald J et al.: Streptozotocin in the treatment of cancer. Cancer 30:61–69, 1972.

    Article  Google Scholar 

  21. Broder LE, Carter SK: Streptozotocin: clinical brochure. Therapy Evaluation Program, National Cancer Insitute, Bethesda, Maryland.

    Google Scholar 

  22. Yunis AA, Arimura CK, Russin DJ: Human pancreatic carcinoma (MIA PaCa–2) in continuous culture: sensitivity to asparaginase. Int. J. Cancer 19:128–135, 1977.

    Article  PubMed  CAS  Google Scholar 

  23. Schein PS, Lavin PT, Moertel CG et al.: Randomized phase II clinical trial of Adriamycin in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group report. Cancer 42:19–22, 1978.

    Article  PubMed  CAS  Google Scholar 

  24. Reitermeier RJ, Moertel CG, Hahn RG: Combination chemotherapy in gastrointestinal cancer. Cancer Res 30:1425–1428, 1970.

    Google Scholar 

  25. Kovach JS, Moertel CG, Schutt AJ, Hahn RG, Reitermeier RJ: A controlled study of combined 1,3-bis (2-chloroethyl)-l-nitrosoureas and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 33:563–567, 1974.

    Article  PubMed  CAS  Google Scholar 

  26. Lokich JJ, Skarin AT: Combination therapy with 5-fluorouracil (5-FU) and 1,3-bis (2-chlorethyl)-l-nitrosourea (BCNU) for disseminated gastrointestinal carcinoma. Cancer Che-mother Rep 56:653–657, 1972.

    CAS  Google Scholar 

  27. Buroker T, Kim PN, Heilbrun L et al.: 5-FU infusion with mitomycin C (MMC) vs 5-FU infusion with methyl CCNU (Me) in the treatment of advanced upper gastrointestinal cancer. Proc ASCO 19:310, 1978.

    Google Scholar 

  28. Horton J, Gelber R: Trials of single agent and combination chemotherapy in advanced cancer of the pancreas. Proceedings ASCO 21:420, 1980.

    Google Scholar 

  29. Wiggans, G, Woolley PV, Macdonald JS et al.: Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer 41:387–391, 1978.

    Article  PubMed  CAS  Google Scholar 

  30. Aberhalden RT, Bukowski RM, Groppe CW et al.: Streptozotocin (STZ) and 5-fluorouracil (5-FU) with and without mitomycin-C (Mito) in the treatment of pancreatic adenocarcinoma. Proc ASCO 18:301, 1977.

    Google Scholar 

  31. Bitran JD, Desser RK, Kozloff MF, Billings AA, Shapiro, CM: Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, Adriamycin, and mitomycin-C (FAM). Cancer Treatment Rep 63:2049–2051, 1979.

    CAS  Google Scholar 

  32. Brown JC, Bruckner HW, Storch J, Schamberlain J, Pressmen PI: Combination chemotherapy for pancreatic cancer. Proc ASCO 21:420, 1980.

    Google Scholar 

  33. Awrich A, Fletcher WS, Klotz JH, Minton JP, Hill GJ II, Aust GJ, Grage TB, Multhauf BP: 5-FU versus combination therapy with tubercidin, streptozotocin, and 5-FU in the treatment of pancreatic carcinomas: COG Protocol 7230. J Surg Oncol 12:267–273, 1979.

    Article  PubMed  CAS  Google Scholar 

  34. Hall SW, Benjamin RS, Murphy WK, Valdivieso M, Bodey GP: Adriamycin, BCNU, ftorafur chemotherapy of pancreatic and biliary tract cancer. Cancer 44:2008–2013, 1979.

    Article  PubMed  CAS  Google Scholar 

  35. Costanzi JJ, Panettiere FJ, Wolma FJ: Combination chemotherapy for advanced pancreatic carcinoma. Texas Med 75:50–51, 1979.

    CAS  Google Scholar 

  36. Haslam JB, Cavanaugh PJ, Stroup SL: Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer 32:1341–1345, 1973.

    Article  PubMed  CAS  Google Scholar 

  37. Moertel CG, Childs DS, Reitemeier RJ et al.: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865–867, 1969.

    Article  PubMed  CAS  Google Scholar 

  38. Moertel CG, Lokich JJ, Schein PS et al.: An evaluation of high dose radiation and combined radiation and 5-fluorouracil therapy for locally unresectable pancreatic carcinoma. Proc ASCO 17:244, 1976.

    Google Scholar 

  39. The Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. Annls Surg 189:205–208, 1979.

    Google Scholar 

  40. Catterall M: A report of three years’ fast neutron therapy from the medical research council’s cyclotron at Hammersmith Hospital, London. Cancer 34:91–95, 1974.

    Article  PubMed  CAS  Google Scholar 

  41. Wasserman TH, Comis RL, Goldsmith M, Handelsman H, Penta JS, Slavik M, Soper WT, Carter SK: Tabular analysis of the clinical chemotherapy of solid tumors. Cancer Chemother Rep 6:399, 1975.

    Google Scholar 

  42. Moertel CG: Clinical management of advanced gastrointestinal cancer. Cancer 36:675–682, 1975.

    Article  PubMed  CAS  Google Scholar 

  43. Heidelberger C: Fluorinated pyrimidines, a new class of tumor inhibitory compound. Nature 179:663–666, 1957.

    Article  PubMed  CAS  Google Scholar 

  44. Moertel CG, Reitemeier RJ, Hahn RG: Therapy with the fluorinated pyrimidines. In: Advanced gastrointestinal cancer, Moertel CG, Reitemeier RJ (eds). New York: Koeber, 1969, pp 86–107.

    Google Scholar 

  45. Moertel CG: Clinical management of advanced gastrointestinal cancer. Cancer 36:675–682, 1975.

    Article  PubMed  CAS  Google Scholar 

  46. Carter SK: Large bowel cancer — The current status of treatment. J Nat Cancer Inst 56:3–10, 1976.

    PubMed  CAS  Google Scholar 

  47. Jacobs EM, Reeves WJ, Wood DA, Pugh R, Braunwald J, Bateman JR: Treatment of cancer with weekly intravenous 5-fluorouracil. Cancer 27:1302–1305, 1971.

    Article  PubMed  CAS  Google Scholar 

  48. Leone LA: The chemotherapy of colorectal cancer. Cancer 34:972–976, 1974.

    Article  PubMed  Google Scholar 

  49. Scifert P, Baker LH, Reed ML, Vaitkevicius VK: Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36:123–128, 1975.

    Article  Google Scholar 

  50. Khung CL, Hall TC, Piro AJ, Dederick MM: A clinical trial of oral 5-fluorouracil. Clin Pharmacol. Ther 7:527–533, 1966.

    PubMed  CAS  Google Scholar 

  51. Lahiri, SR, Boileau G, Hall TC: Treatment of metastatic colorectal carcinoma with 5-fluorouracil by mouth. Cancer 28:902–906, 1971.

    Article  PubMed  CAS  Google Scholar 

  52. Bateman J, Irwin L, Pugh R et al.: Comparison of intravenous and oral administration of 5-fluorouracil for colorectal carcinoma. Proc Am Assoc Cancer Res 16:242, 1975.

    Google Scholar 

  53. Ansfield R, Klotz J, Nealon T, Ramirez G, Minton J, Hill G, Wilson W, Davis H, Cornell G: A phase III study comparing the clinical utility of four regimens of 5-fluorouracil. Cancer 39:34, 1977.

    Article  PubMed  CAS  Google Scholar 

  54. Hahn RG, Moertel CG, Schutt AJ, Bruckner HW: A double-blind comparison of intensive course 5-FU by oral vs intravenous route in the treatment of colorectal carcinoma. Cancer 35:1031–1035, 1975.

    Article  PubMed  CAS  Google Scholar 

  55. Valdivieso M, Bodey GP, Gottlieb JA, Freireich EJ: Clinical evaluation of ftorafur. Cancer Res 36:1821, 1976.

    PubMed  CAS  Google Scholar 

  56. Buroker T, Wojtaszak B, Dindogru A, DeMattia M, Baker L, Groth C, Vaitkevicius VK: Phase II trial of ftorafur with mitomycin C. versus ftorafur with methyl CCNU in untreated colorectal cancer. Cancer Treatment Rep 62:689, 1978.

    CAS  Google Scholar 

  57. Buroker T, Padilla F, Groppe C et al.: Phase II evaluation of ftorafur in previously untreated colorectal cancer. A Southwest Oncology Group Study. Cancer 44:48, 1979.

    Article  PubMed  CAS  Google Scholar 

  58. Comis RL, Carter SK: A review of chemotherapy in gastric cancer. Cancer 34:1576–1586, 1974.

    Article  PubMed  CAS  Google Scholar 

  59. Moertel CG: Therapy of advanced gastrointestinal cancer with the nitrosoureas. Cancer Chemother. Rep. (Part 3), No. 3, 4:27–34, 1973.

    CAS  Google Scholar 

  60. Hoth D, Butler T, Winokur S, Kales A, Woolley P, Schein P: Phase II study of chlorozotocin. Proc Am Assoc Cancer Res Am Soc Clin Oncol 19:381, 1978.

    Google Scholar 

  61. Carter SK, Freidman M: Integration of chemotherapy into combined modality treatment of solid tumors. II. Large bowel cancer. Cancer Treatment Rev 1:111, 1974.

    Article  Google Scholar 

  62. DiBeneditto J, Moayeri H, Evans JT, Mittleman A: Phase II study of melphalan in colorectal carcinoma. Cancer Treatment Rep 62:1401, 1978.

    Google Scholar 

  63. Cashmore AR, Skeel RT, Makulu, Dr, Gralla EJ, Bertino, JR: Pharmacology of a new triazine antifolate in mice, rats, dogs and monkeys. Cancer Res 35:17, 1975.

    PubMed  CAS  Google Scholar 

  64. Padilla F, Correa J, Buroker T, Vaitkevicius VK: Phase II study of Baker’s antifol in advanced colorectal cancer. Cancer Treatment Rep 62:553, 1978.

    CAS  Google Scholar 

  65. Biermann WA, Catalano RB, Engstrom PF: A positive Phase II study of dibromodulcitol in previously treated patients with advanced colorectal carcinoma. Proc Am Assoc. Cancer Res 20:341, 1979.

    Google Scholar 

  66. Joss RA, Goldberg RS, Yates JW: Combination chemotherapy of colorectal cancer with 5-fluorouracil, methyl-1, 3-cis (2-chloroethyl)-l-nitrosourea, and vincristine. Med. Pediatr. Oncol 7:251–255, 1979.

    Article  PubMed  CAS  Google Scholar 

  67. Frytak S, Moertel CG, Childs DS, Schutt AJ, Albers JW: Phase II study of metronidazole therapy for advanced colorectal carcinoma. Cancer Treatment Rep 62:483, 1978.

    CAS  Google Scholar 

  68. Moertel CG, Schutt AJ, Hahn RG, Marciniak TA, Reitemeier, RJ: Phase II study of chromomycin A3 (NSC 58514) in advanced colorectal cancer. Cancer Chemother Rep 59:577–579, 1975.

    PubMed  CAS  Google Scholar 

  69. Moertel CG, Schutt AJ, Hahn RG, Marciniak TA, Reitemeier, RJ: Phase II study of cytembena (NSC 104801) in advanced colorectal cancer. Cancer Chemother Rep 59:581–583, 1975.

    PubMed  CAS  Google Scholar 

  70. Creagan ET, Rubin J, Moertel CG, Schutt AJ, O’Connell MJ, Hahn RG, Reitemeier RJ, Frytak S: Phase II study of pyrazofurin in advanced colorectal carcinoma. Cancer treatment Rep 61:491, 1977.

    CAS  Google Scholar 

  71. Cullinan SA, O’Connell MJ, Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ, Frytak S, Rubin J: Phase II study of cytosine arabinoside in advanced large bowel cancer. Cancer Treatment Rep 61:1725, 1977.

    CAS  Google Scholar 

  72. O’Connell, MJ, Shani A, Rubin J, Moertel CG: Phase II trial of maytansine in patients with advanced colorectal carcinoma. Cancer Treatment Rep 62:1237, 1978.

    CAS  Google Scholar 

  73. Corroll DS, Kemeny NE: Vindesine DVA in the treatment of patients with metastatic colorectal carcinoma. Proc Am Assoc Cancer Res 20:195, 1979.

    Google Scholar 

  74. Bedikian AY, Valdivieso M, Bodey GP, Freireich EJ: Phase II evaluation of vindesine in the treatment of colorectal and esophageal tumors. Cancer Chemother Pharmacol 2:263–266, 1979.

    Article  PubMed  CAS  Google Scholar 

  75. Kemeny N, Yagoda A, Burchenl JH: Phase II study of 2,2’ anhydro-1-beta-D-arabinofura-nosyl-5-fluorocytosine in advanced colorectal carcinoma. Cancer Treatment Rep 62:463, 1978.

    CAS  Google Scholar 

  76. Diggs CH, Scoltock MJ, Wiernik PH: Phase II evaluation of enguidine (NSC-141537) for adenocarcinoma of the colon or rectum. Cancer Clin Trials 1:297–299, 1978.

    PubMed  CAS  Google Scholar 

  77. Douglass HO Jr, Lavin PT, Evans JT, Mittelman A, Carbone, PP: Phase II evaluation of digycoaldehyde, VP-16-213, and the combination of methyl-CCNU and beta-2’-deoxythio-guanosine in previously treated patients with colorectal cancer: an Eastern Cooperative Oncology Group Study (EST-1275).

    Google Scholar 

  78. Moertel CG, Reitemeier RJ, Hahn RG: Combination chemotherapy in advanced gastrointestinal cancer. Cancer Res, 30:1425–1428, 1970.

    PubMed  Google Scholar 

  79. Falkson G, Van Eden EG, Falkson HC: Fluorouracil, imidazole carboximide dimethyltriazeno, vincristine and bis-cholorethylnitrosourea in colon cancer. Cancer 33:1207–1209, 1974.

    Article  PubMed  CAS  Google Scholar 

  80. Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ: Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-1, 3-cis (2-chlorethyl)-l-nitrosourea and vincristine. J Nat Cancer Inst 54:69–71, 1975.

    PubMed  CAS  Google Scholar 

  81. Falkson G, Falkson HC: Fluorouracil, methyl-CCNU, and vincristine in cancer of the colon. Cancer 38:1468–1470, 1976.

    Article  PubMed  CAS  Google Scholar 

  82. Macdonald JS, Kisner DF, Smythe T, Woolley PV, Smith L, Schein PS: 5-Fluorouracil (5-FU), methyl-CCNU and vincristine in the treatment of advanced colorectal cancer. Phase II study utilizing weekly 5-FU. Cancer Treatment Rep 60:1597–1600, 1976.

    CAS  Google Scholar 

  83. Engstrom P, MacIntyre J, Douglass H Jr, Carbone P: Combination chemotherapy of advanced bowel cancer. Proc Am Assoc Cancer Res Am Soc Clin Oncol 19:384, 1978.

    Google Scholar 

  84. Kemeny N, Yagoda A, Golbey R: Randomized study of 2 different schedules of methyl CCNU (MeCCNU), 5-fluorouracil (5-FU), and vincristine (VCR) for metastatic colorectal carcinoma. Proc Am Assoc Cancer Res Am Soc Clin Oncol 18:336, 1977.

    Google Scholar 

  85. Moertel CG: Chemotherapy of gastrointestinal cancer. N Eng J Med 299:1049, 1978.

    Article  CAS  Google Scholar 

  86. Posey L, Morgan LR: Methyl CCNU versus methyl CCNU and 5-fluorouracil in carcinoma of the large bowel. Cancer Treatment Rep 61:1453, 1977.

    CAS  Google Scholar 

  87. Baker LH, Talley RW, Matter R, Lehane DE, Ruffner BW, Jones SE, Morrison FS, Stephens RL, Gehan EA, Vaitkevicius, VK: Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU: a Southwest Oncology Group Study. Cancer 38:1–7, 1976.

    Article  PubMed  CAS  Google Scholar 

  88. Lokich JJ, Skarin AT, Mayer RJ, Frei E: Lack of effectiveness of combined 5-fluorouracil and methyl CCNU therapy in advanced colorectal cancer. Cancer 40:2792–2796, 1977.

    Article  PubMed  CAS  Google Scholar 

  89. Buroker T, Kim PN, Heibrun L: 5-FU infusion with mitomycin in C vs. 5-FU infusion with methyl CCNU in the treatment of advanced colon cancer: a Phase III study. Proc Am Assoc Cancer Res Am Soc Clin Oncol 18:271, 1977.

    Google Scholar 

  90. Berman R, Giles GR, Malhutra A, Bird GG, Gajjar, PD, Bunch, GA, Hall R: Randomized trial of melphalan plus 5-fluorouracil (5-FU) versus methyl CCNU plus 5-FU in patients with advanced colorectal cancer. Cancer Treatment Rep 62:457, 1978.

    CAS  Google Scholar 

  91. Kane RC, Cashdollar MR, Bernath AM: Treatment of advanced colorectal cancer with methyl CCNU plus 5 day 5-fluorouracil infusion. Cancer Treatment Rep 62:1521–1525, 1978.

    CAS  Google Scholar 

  92. Buroker T, Kim PN, Groppe C, McCracken J, O’Bryan R, Panettiere F, Coltman C, Bottomley R, Wilson H, Bonnett J, Thigpen T, Vaitkevicuis VK, Hoogstraten B, Hellrum L: 5-Fluorouracil infusion with mitomycin vs. 5-FU infusion with methyl-CCNU in the treatment of advanced colon cancer. A Southwest Oncology Group Study. Cancer 42:1228, 1978.

    CAS  Google Scholar 

  93. Vaughn CB, Brady P, Chinn BJ, Daversa GC, Parzuchowski JS: Combination chemotherapy in advanced gastrointestinal malignancy. Oncology 37:57–61, 1980.

    Article  PubMed  CAS  Google Scholar 

  94. Buroker T, DeMattie M, Baker L, Groth C, Vaitkevicius VK, Wojtasak B, Dindognu A: Phase II trial of ftorafur with mitomycin-C versus ftorfur with methyl-CCNU in untreated colorectal Cancer. Cancer Treatment Rep 62:689, 1978.

    CAS  Google Scholar 

  95. Kemeny N, Yagoda, A, Braun D Jr, Golbey R: A randomized study of two different schedules of methyl-CCNU, 5-FU, and vincristine for metastatic colorectal carcinoma. Cancer 43:78–82, 1979.

    Article  PubMed  CAS  Google Scholar 

  96. Kemeny N, Yagoda A, Golbey R: A prospective randomized study of methyl-CCNU, 5-fluoruracil, and vincristine (MOF) vs. MOF plus streptozotocin (MOF-Strep) in patients with metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 21:417, 1980.

    Google Scholar 

  97. White LA Jr, Perry MC, Kardinal CG, Kennedy BJ, Weiss, RB, Carey RW: Phase II study of 5-fluourouracil, methyl-CCNU, and daunorubicin in colorectal cancer. A Cancer and Leukemia Group B Study. Cancer Treatment Rep 63:215–217, 1979.

    Google Scholar 

  98. Shaw MT, Heilbrum LK: Baker’s antifol (BAF) in combination with methyl-CCNU and 5-fluorouracil (5-FU) for the treatment of metastatic colorectal cancer. Proc Am Assoc. Cancer Res 20:300, 1979.

    Google Scholar 

  99. Presant CA, Ratkin G, Klahr C: Phase II study of mitomycin C, cyclophosphamide, and methotrexate in drug-resistant colorectal carcinoma. Cancer Treatment Rep 62:549, 1978.

    CAS  Google Scholar 

  100. Presant CA, Ratkin G, Klahr C: Phase II trial of 5-fluorouracil plus melphalan in colorectal carcinoma. Cancer Treatment Rep 62:461, 1978.

    CAS  Google Scholar 

  101. Bedikian AY, Staab R, Livingston R, Valdivieso M, Burgess MA, Bodey GP: Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: comparison of oral and continuous IV administration of 5-fluorouracil. Cancer Treatment Rep 62:1603, 1978.

    CAS  Google Scholar 

  102. White DR, Richards FD, Muss HB, Cooper MR, Spurr CL: Therapy of advanced colorectal carcinoma with 5-fluorouracil and cyclophosphamide in combination with either CCNU or methotrexate. Cancer 45:662–665, 1980.

    Article  PubMed  CAS  Google Scholar 

  103. Seligman M, Bukowski RM, Groppe CW, Weick JK, Hewlett JS, Greenstreet RL: Chemotherapy of metastatic gastrointestinal neoplasms with 5-fluorouracil and streptozotocin. Cancer Treatment Rep 61:1375, 1977.

    CAS  Google Scholar 

  104. Haller DG, Woolley PV, MacDonald JS, Smith LF, Schein PS: Phase II trial of 5-fluorouracil, Adriamycin, and mitomycin-C in advanced colorectal cancer. Cancer Treatment Rep 62:563, 1978.

    CAS  Google Scholar 

  105. Kessinger MA, Foley JF, Lemon HM: Adriamycin, mitomycin-C, and 5-fluorouracil in combination for advanced colorectal adenocarcinoma previously treated with 5-fluorouracil. Cancer Clin Trials 2:317–319, 1979.

    PubMed  CAS  Google Scholar 

  106. Davis S, Park YK: Chemotherapy for colorectal cancer with a combination of 5-fluorouracil, mitomycin-C, Adriamycin, and cytosine arabinoside: a pilot study. Cancer Treatment Rep 62:1557–1559, 1978.

    CAS  Google Scholar 

  107. Murphy WK, Valdivieso M, Burgess MA, Bodey GP: Chemotherapy of advanced colorectal cancer and other malignancies with 5-fluorouracil (5-FU) and anguidine (ANG). Proc Am Assoc Cancer Res 20:419, 1979.

    Google Scholar 

  108. Woodcock TM, Martin DS, Damin LA, Kemeny NE, Young CW: Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation. Cancer 45:1135–1143, 1980.

    Article  PubMed  CAS  Google Scholar 

  109. Vogel SJ, Presant CA, Ratkin GA, Klahr C: Phase I study of thymidine plus 5-fluorouracil infusions in advanced colorectal carcinoma. Cancer Treatment Rep 63:1–5, 1979.

    CAS  Google Scholar 

  110. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG: Therapy for gastrointestinal cancer with the nitrosoureas alone and in drug combination. Cancer Treatment Rep 60:729, 1976.

    CAS  Google Scholar 

  111. Douglass HO, Lavin PT, Moertel CG: Nitrosoureas: useful agents for the treatment of advanced gastrointestinal cancer. Cancer Treatment Rep 60:769, 1976.

    Google Scholar 

  112. DiBenedetto J, Moayeri H, Evans JT, Mittelman A: Phase II study of melphalan in colorectal carcinoma. Cancer Treatment Rep 62:1401, 1978.

    Google Scholar 

  113. McCreary RH, Moertel CG, Schutt AJ, O’Connell MJ, Hahn RG, Reitemeier RJ, Rubin J, Frytak S: A phase II study of triazinate (NSC 139105) in advanced colorectal carcinoma. Cancer 40:9, 1977.

    Article  PubMed  CAS  Google Scholar 

  114. Taylor SG, Desai SA, DeWys WD: Phase II trial of a combination of cyclophosphamide, vincristine, and methotrexate in advanced colorectal carcinoma. Cancer Treatment Rep 62:1203, 1978.

    Google Scholar 

  115. Ackerman NB, Lien WM, Kondi ES, Silverman NA: The blood supply of experimental liver metastases. 1. The distribution of hepatic artery and portal vein blood to’ small’ and ‘large’ tumors. Surgery 66:1067–1072, 1969.

    PubMed  CAS  Google Scholar 

  116. Mann JD, Wakitn KG, Baggenstoss AH: The vasculature of the human liver — a study by injection-cast method. Proc Mayo Clin 28:227–232, 1953.

    CAS  Google Scholar 

  117. Healey JE: Vascular patterns in human metastatic liver tumors. Surg Gynecol Obstet 120:1187–1194, 1965.

    PubMed  Google Scholar 

  118. Bierman HR, Byron RL, Kelley KH, Grady A: Studies on blood supply of tumors in man; III. Vascular patterns of liver by hepatic arteriography in vivo. J Nat Cancer Inst 12:107, 1951-1952.

    PubMed  CAS  Google Scholar 

  119. Ansfield FJ, Ramirez G, Davis HL, Wirtaneu GW, Johnson RO, Davis TE, Esmaili M, Bryan GRT, Manolo FB, Bordeu EC: Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer 36:2413, 1975.

    Article  PubMed  CAS  Google Scholar 

  120. Buroker T, Samson M, Correa J, Fraile R, Vaitkevicius VK: Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil. Cancer Treatment Rep 60:1277, 1976.

    CAS  Google Scholar 

  121. Oberfield RA, McCaffrey JA, Polio J, Clouse ME, Hamilton T: Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary. Cancer 44:414–423, 1979.

    Article  PubMed  CAS  Google Scholar 

  122. Ansfield FJ, Ramirez G: The clinical results of 5-FU intrahepatic arterial infusion in 528 patients with metastatic cancer to the liver: In: Progress in clinical cancer, vol 7. Ariel IM (ed). New York: Grune & Stratton, 1978.

    Google Scholar 

  123. Grage TB, Vassilopoulos PP, Shingleton WW, Jubert AV, Elias, EG, Aust JB, Moss SE: Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: a Central Oncology Group Study. Surgery 86:550–555, 1979.

    PubMed  CAS  Google Scholar 

  124. Kinami Y, Miyazaki J. The superselective and the selective one shot method for treating inoperable cancer of the liver. Cancer 41:1720, 1978.

    Article  PubMed  CAS  Google Scholar 

  125. Misra NC, Jaiswal MSD, Singh RV, Das B. Intrahepatic arterial infusion of combination of mitomycin C and 5-fluorouracil in treatment of primary and metastatic liver carcinoma. Cancer 39:1425, 1977.

    Article  PubMed  CAS  Google Scholar 

  126. Douglass CC: Improved survival in liver metastases from colorectal carcinoma following periodic arterial infusions with mitomycin-C, 5-fluorouracil, adriamycin, velban and vincristine. Proc Am Assoc Cancer Res 20:431, 1979.

    Google Scholar 

  127. Hoth DF, Petrucci PE. Natural history and staging of colon cancer. Seminars in Oncology; Colon cancer, vol. III, No. 4, 1976.

    Google Scholar 

  128. Higgans GA Jr, Humphrey E, Juler GL, LeVeen HH, McCaughan J, Keehn RJ: Adjuvant chemotherapy in the surgical treatment of large bowel cancer. Cancer 38:1461–1467, 1976.

    Article  Google Scholar 

  129. Grage TB, Hill GJ, Cornell GN, Frelick RW, Moss SE: Adjuvant chemotherapy in large bowel cancer: demonstration of effectiveness of single agent chemotherapy in a prospec-tively controlled, randomized trial. Rec Res Cancer Res. 68:222–230, 1978.

    CAS  Google Scholar 

  130. Taylor I, Rowling J, West C: Adjuvant cytotoxic liver perfusion for colorectal cancer. Br J Surg 66:833–837, 1979.

    Article  PubMed  CAS  Google Scholar 

  131. Moertel CG, O’Connell MJ, Ritts RE, Schutt AJ, Reitemeier, RJ, Hahn RG, Frytak SK, Rubin J: A controlled evaluation of combined immunotherapy (MER-BCG) and chemotherapy for advanced colorectal cancer. In: Immunotherapy of cancer: present status of trials in man, Terry WD, Windhorst D (eds). New York: Raven Press, 1978, p 573.

    Google Scholar 

  132. Engstrom PF, Paul AR, Catalano RB, Mastrangelo MJ, Creech RH: Fluorouracil versus fluorouracil + BCG in colorectal adenocarcinoma, In: Immunotherapy of cancer: present status of trials in man, Terry WE, Windhorst D (eds). New York: Raven Press, 1978, p 587.

    Google Scholar 

  133. Gough IR, Clunie GJ, Bolton PM, Dury M, Burnett W: A trial of 5-fluorouracil and corynebacterium parvum in advanced colorectal carcinoma. Dis Colon Rectum 22:223–227, 1979.

    Article  PubMed  CAS  Google Scholar 

  134. Gunderson LL: Radiation therapy: results and future possibilities. Clin Gastroenterol 5:743, 1976.

    PubMed  CAS  Google Scholar 

  135. Quan SH: Preoperative radiation for carcinoma of the rectum. NY State J Med 66:2243, 1966.

    Google Scholar 

  136. Stearns MW, Deddish MR, Quan SH, Learning RH: Preoperative roentgen therapy for cancer of the rectum and rectosigmoid. Surg Gynecol Obstet 138:584, 1975.

    Google Scholar 

  137. Higgins GA, Conn JH, Jordan PH, Humphrey EW, Roswit B, Keehn RJ: Preoperative radiotherapy for colorectal cancer. Ann Surg 181:624–631, 1975.

    Article  PubMed  Google Scholar 

  138. Roswit B, Higgins GA, Keehn RJ: Preoperative irradiation for carcinoma of the rectum and rectosigmoid colon: report of a National Veterans Administration randomized study. Cancer 35:1597, 1975.

    Article  PubMed  CAS  Google Scholar 

  139. Kligerman MR: Radiation therapy for rectal carcinoma. Semin Oncol 3:407, 1976.

    PubMed  CAS  Google Scholar 

  140. Comis RL, Carter SK: Cancer 34:1576–1586, 1974.

    Article  PubMed  CAS  Google Scholar 

  141. Woolley PV, MacDonald JS, Schein PS: Chemotherapy of malignancies of the gastrointestinal tract. Progr. Gastroen 3:671, 1977.

    Google Scholar 

  142. Kovach JS, Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ: A controlled study of combined l,3-bis-(2-chloroethyl)-l-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 33:563, 1974.

    Article  PubMed  CAS  Google Scholar 

  143. Moertel CG, Mittelman JA, Bakemeier RF, Engstrom P, Hanley J: Sequential and combination chemotherapy of advanced gastric cancer. Cancer 38:678, 1976.

    Article  PubMed  CAS  Google Scholar 

  144. Kingston RD, Ellis DJ, Powell J, Brookes VS, Waterhouse JA, Hurst MD, Smith JA: The West Midlands gastric carcinoma chemotherapy trial: planning and results. Clin Oncol 4:55, 1978.

    PubMed  CAS  Google Scholar 

  145. Moertel CG, Lavin RT: Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treatment Rep 63:1863–1869, 1979.

    CAS  Google Scholar 

  146. Buroker T, Kim PN, Groppe C, McCracken J, O’Bryan R, Pannettiere F, Costanzi J, Bottomley R, King GW, Bonnet J, Thigpen T, Whitecar J, Hass C, Vaitkevicius VK, Hoogstraten, B, Heilbrun L: 5-FU infusion with mitomycin-C vs. 5-FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer. A Southwest Oncology Group Study. Cancer 44:1215, 1979.

    Article  PubMed  CAS  Google Scholar 

  147. Ota K, Kurita S, Nishimura M, Ogawa M, Kamei Y, Imai K, Ariyoshi Y, Kataoka K, Murakami MO, Oyama A, Hoshino A, Arno H, Kato T: Combination therapy with mitomycin-C, 5-fluorouracil and cytosine arabinoside for advanced cancer in man. Cancer Chemother Rep 56:373, 1972.

    PubMed  CAS  Google Scholar 

  148. DeJager RL, Magill Gb, Golbey RB Krakoff IH: Combination chemotherapy with mitomycin C, 5-fluorouracil, and cytosine arabinoside in gastrointestinal cancer. Cancer Treatment Rep 60:1373–1375, 1976.

    CAS  Google Scholar 

  149. The Gastrointestinal Tumor Study Group. Phase II-III chemotherapy study in advanced gastric cancer. Cancer Treatment Rep 63:1971, 1979.

    Google Scholar 

  150. MacDonald JS, Wolley PV, Smythe T, Ueno W, Hoth D, Schein PS: 5-Fluorouracil, Adriamycin and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 44:42, 1979.

    Article  PubMed  CAS  Google Scholar 

  151. MacDonald JS, Schein PS, Woolley PV, Boiron M, Gisselbrecht, C, Brunet R, Lagarde C: 5-Fluorouracil (5-FU), Mitomycin-C (MMC) and Adriamycin (ADR) FAM combination chemotherapy results in 61 patients with advanced gastric cancer. Proc Am Soc Clin Oncol 20:434, 1979.

    Google Scholar 

  152. Panettiere F, Heilbrun L: Comparison of two different combinations of Adriamycin, mitomycin-C and 5-FU in the management of gastric carcinoma. A SWOG study. Proc AM. Soc. Clin Oncol 20:315, 1979.

    Google Scholar 

  153. Bernath AM, Thornsvard CT: Treatment of advanced gastric carcinoma with BCNU, Adriamycin, 5-FU, and mitomycin-C (BAFMI). Proc Am Soc Clin Oncol 20:312, 1979.

    Google Scholar 

  154. Lacave AJ, Brugarolas A, Buesa JM, Garcia Moran M, Perez Ricarte P, Garcia Muniz L, Astudillo A, Urrutia C: Methyl-CCNU (Me), 5-Fluorouracil (F), Adriamycin (A) (MeFA) versus MeF in advanced gastric Cancer. Proc Am Soc Clin Oncol 20:310, 1979.

    Google Scholar 

  155. Levi JA, Dalley DM, Aroney RS: Improved combination chemotherapy in advanced gastric cancer. Br Med J 2:1471, 1979.

    Article  PubMed  CAS  Google Scholar 

  156. Magill GB, Golbey RB, Burchenal JH: Combined anhydro-ara-5-fluorocytidine (AAFC) and cis-platinum diamminedichloride (PPD) therapy in gastric and pancreatic carcinoma. Proc Am Soc Clin Oncol 19:353, 1978.

    Google Scholar 

  157. VASAG — Veteran’s Administration Cooperative Surgical Adjuvant Study Group. Use of thiotepa as an adjuvant to surgical management of carcinoma of the stomach. Cancer 18:291, 1965.

    Article  Google Scholar 

  158. Hattori T, Ito I, Katsvr H, Hirata K, Iizuka T, Abe K: Results of combined treatment in patients with cancer of the stomach: Palliative gastrectomy, large dose mitomycin-C, and bone marrow transplantation. Gann 57:441, 1966.

    PubMed  CAS  Google Scholar 

  159. Serlin O, Wolhoff JS, Amadeo JM, Keehn RJ: Use of 5-fluorodeoxyuridine (FUDR) as an adjuvant to surgical management of carcinoma of the stomach. Cancer 24:223, 1969.

    Article  PubMed  CAS  Google Scholar 

  160. Nakajima T, Fukami A, Ohashi I, Kajitani T: Long-term follow-up Study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol Biopharm 16:209–216, 1978.

    PubMed  CAS  Google Scholar 

  161. Nakajima T, Ota H, Takagi K, Kajitani T: Combination of multidrug therapy (i.v.) and Long-term oral chemotherapy as an adjuvant to surgery for gastric cancer. J Jpn Soc Cancer Ther 15th Cong. 226, 1977.

    Google Scholar 

  162. Moertel CG, Childs DS, Reitemeier R, Colby MY, Holbrook MA: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865, 1969.

    Article  PubMed  CAS  Google Scholar 

  163. Schein PS, Childs D: For GITSG. A Controlled randomized evaluation of combined modality therapy (5000 rads, 5-FU + MeCCNU) vs. 5-FU + MeCCNU alone for locally advanced gastric cancer. Proc. Am Soc Clin Oncol 19:C–329, 1978.

    Google Scholar 

  164. Schein PS, Novak J: For the Gastrointestinal Tumor Study Group. Combined modality therapy (XRT-chemo) versus chemotherapy alone for locally unresectable gastric cancer. Proc Am Soc Clin Oncol 21:419, 1980.

    Google Scholar 

Download references

Authors
  1. John R. Neefe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip S. Schein
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, New York, USA

    Jerome J. Decosse  & Paul Sherlock  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1981 Martinus Nijhoff Publishers, The Hague/Boston/London

About this chapter

Cite this chapter

Neefe, J.R., Schein, P.S. (1981). Chemotherapy of Pancreatic, Colorectal and Gastric Cancer. In: Decosse, J.J., Sherlock, P. (eds) Gastrointestinal Cancer 1. Cancer Treatment and Research, vol 3. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-8255-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-8255-0_15

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-009-8257-4

  • Online ISBN: 978-94-009-8255-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation